Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: The case of anamorelin

Stefan D. Anker, Andrew J S Coats, John E. Morley

Research output: Contribution to journalArticle

Abstract

A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.

Original languageEnglish
Pages (from-to)275-277
Number of pages3
JournalJournal of Cachexia, Sarcopenia and Muscle
Volume6
Issue number4
DOIs
Publication statusPublished - 2015

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: The case of anamorelin'. Together they form a unique fingerprint.

  • Cite this